FDA Approves New First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
March 30, 2020
On March 27, 2020, the Food and Drug Administration (FDA) approved Imfinzi (durvalumab) in combination with etoposide and either carboplatin or cisplatin as first line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). The FDA based their approval on the results of the clinical trial CASPIAN which showed patients receiving Imfinzi in combination with chemotherapy lived longer, had more time without disease progression, and a higher percentage of patients experiencing a response to treatment than those on chemotherapy alone.Imfinzi is only the second immunotherapy drug to be approved by the FDA for first line treatment of small cell lung cancer. This gives patients more options in the fight against small cell lung cancer.Click here to view full press release.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.